<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tretinoin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00755</strong>&#160; (APRD00362, NUTR00051)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational, nutraceutical</td></tr><tr><th>Description</th><td><p>Tretinoin, also known as all-trans-retinoic acid (<span class="caps">ATRA</span>), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (<span class="caps">APL</span>).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00755/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00755/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00755.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00755.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00755.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00755.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00755.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00755">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>All Trans Retinoic Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>All Trans-Retinoic Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>ATRA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Retionic Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Tretinoin</td><td>German</td><td>INN</td></tr><tr><td>Tretinoina</td><td>Spanish</td><td>INN</td></tr><tr><td>Tr&#233;tino&#239;ne</td><td>French</td><td>INN</td></tr><tr><td>Tretinoinum</td><td>Latin</td><td>INN</td></tr><tr><td>Vitamin A acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aberel</td><td>Janssen</td></tr><tr><td>Aberela</td><td>Janssen</td></tr><tr><td>Airol</td><td>Pierre Fabre Dermo</td></tr><tr><td>Amnesteem</td><td>Mylan Pharmaceuticals</td></tr><tr><td>Atralin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Avita</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Claravis</td><td>Barr Laboratories Inc.</td></tr><tr><td>Dermairol</td><td>Roche</td></tr><tr><td>Eudyna</td><td>Zydus</td></tr><tr><td>K&#233;trel</td><td>Bailleul</td></tr><tr><td>Refissa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Retin-A</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Retisol-A</td><td>Stiefel</td></tr><tr><td>Sotret</td><td>Ranbaxy Laboratories Inc.</td></tr><tr><td>Stieva-A</td><td>Stiefel</td></tr><tr><td>Tretin-X</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>TRETIN.X</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vesanoid</td><td>Roche</td></tr><tr><td>Vitinoin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Solage</td><td>Mequinol and Tretinoin</td></tr><tr><td>VELTIN</td><td>Tretinoin + Clindamycin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li>
<li><a href="/mesh/keratolytic-agents">Keratolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>302-79-4</td></tr><tr><th>Weight</th><td>Average: 300.4351<br>Monoisotopic: 300.20893014</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>28</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>SHGAZHPCJJPHSC-YCNIQYBTSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Prenol Lipids</td></tr><tr><th>Subclass</th><td>Retinoids</td></tr><tr><th>Direct parent</th><td>Retinoids</td></tr><tr><th>Alternative parents</th><td>Diterpenes; Carbocyclic Fatty Acids; Branched Fatty Acids; Unsaturated Fatty Acids; Enones; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>enone; enolate; polyamine; carboxylic acid; carboxylic acid derivative</td></tr><tr><th>Classification description</th><td>This compound belongs to the retinoids. These are compounds that are related to vitamin A, especially retinol.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.</td></tr><tr><th>Pharmacodynamics</th><td>Tretinoin, also known as all-<i>trans</i>-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).</td></tr><tr><th>Mechanism of action</th><td>Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.</td></tr><tr><th>Absorption</th><td>1-31% (topical)</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>&gt; 95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tretinoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0000421" target="_blank">Cytochrome P450 4A11</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li></ul></td><td><a href="/metabolites/DBMET00298">4-Hydroxyretinoic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/299">Details</a></td></tr><tr><td>Tretinoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0000421" target="_blank">Cytochrome P450 4A11</a></li></ul></td><td><a href="/metabolites/DBMET00453">18-Hydroxyretinoic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/462">Details</a></td></tr><tr><td>Tretinoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li></ul></td><td><a href="/metabolites/DBMET00454">5,6-Epoxyretinoic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/463">Details</a></td></tr><tr><td>Tretinoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0000421" target="_blank">Cytochrome P450 4A11</a></li></ul></td><td><a href="/metabolites/DBMET00455">4-Oxoretinoic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/464">Details</a></td></tr><tr><td>Tretinoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00561">Retinoyl b-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/579">Details</a></td></tr><tr><td>Tretinoin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00594">Retinyl beta-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/612">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>0.5-2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9925</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9311</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7603</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6144</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8912</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8088</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8639</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8221</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6025</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8831</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9301</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9252</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8944
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7081
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5554
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1455 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9562
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9538
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hoffmann la roche inc</li>
<li>Genpharm inc</li>
<li>Barr laboratories inc</li>
<li>Ranbaxy pharmaceuticals inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Mylan bertek pharmaceuticals inc</li>
<li>Ortho dermatologics</li>
<li>Johnson and johnson consumer companies inc</li>
<li>Spear pharmaceuticals inc</li>
<li>Triax pharmaceuticals llc</li>
<li>Dow pharmaceutical sciences inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Ranbaxy Pharmaceuticals Inc.</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.ameri-pac.com">Ameri-Pac Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li><a href="http://www.contractpharma.com">Contract Pharm</a></li>
<li><a href="http://www.corialabs.com">Coria Laboratories</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.dptlabs.com">DPT Laboratories Ltd.</a></li>
<li><a href="http://www.draxispharma.com">Draxis Specialty Pharmaceuticals Inc.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.galderma.com">Galderma Laboratories</a></li>
<li>Genesis Pharmaceutical Inc.</li>
<li><a href="http://www.hilllabs.com">Hill Laboratories Inc.</a></li>
<li><a href="http://www.medicis.com">Medicis Pharmaceutical Co.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.obagi.com">Obagi Medical Products Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho-McNeil-Janssen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.rousespointrx.com">Rouses Point Pharmaceuticals LLC</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.spearpharma.com">Spear Dermatology Products Inc.</a></li>
<li><a href="http://www.stiefel.com">Stiefel Labs</a></li>
<li><a href="http://www.triaxpharma.com">Triax Pharmaceuticals LLC</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Cream</td><td>Topical</td><td></td></tr><tr><td>Gel</td><td>Topical</td><td></td></tr><tr><td>Liquid</td><td>Topical</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1756">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1717">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1718">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1719">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5487">MS/MS Spectrum LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1696">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>The strong CYP2C8 inhibitor, Atazanavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Atazanavir is initiated, discontinued to dose changed. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00482">Celecoxib</a></td><td>The moderate CYP2C8 inhibitor, Celecoxib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Celecoxib is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Demeclocycline may increase the adverse effects of oral Tretinoin. Increased risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00304">Desogestrel</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Desogestrel. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Drospirenone. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>The moderate CYP2C8 inhibitor, Eltrombopag, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Eltrombopag is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Oral Tretinoin may decrease the effect of the oral contraceptive, Ethinyl Estradiol. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00823">Ethynodiol</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Ethynodiol Diacetate. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00294">Etonogestrel</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The strong CYP2C8 inducer, Fosphenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Fosphenytoin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>The strong CYP2C8 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Gemfibrozil is initiated, discontinued to dose changed. </td></tr><tr><td><a href="/drugs/DB01029">Irbesartan</a></td><td>The moderate CYP2C8 inhibitor, Irbesartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Irbesartan is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB01259">Lapatinib</a></td><td>The moderate CYP2C8 inhibitor, Lapatinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Lapatinib is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Levonorgestrel. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>The moderate CYP2C8 inhibitor, Losartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Losartan is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Minocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB04868">Nilotinib</a></td><td>The moderate CYP2C8 inhibitor, Nilotinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Nilotinib is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00957">Norgestimate</a></td><td>Oral Tretinoin may decrease the effect of oral contraceptive, Norgestimate. An alternate form of contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00595">Oxytetracycline</a></td><td>Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The strong CYP2C8 inducer, Phenobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01132">Pioglitazone</a></td><td>The moderate CYP2C8 inhibitor, Pioglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Pioglitazone is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The strong CYP2C8 inducer, Primidone, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Primidone is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>The moderate CYP2C8 inhibitor, Quinine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Quinine is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>The strong CYP2C8 inducer, Rifapentine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifapentine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The strong CYP2C8 inhibitor, Ritonavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Ritonavir is initiated, discontinued to dose changed. </td></tr><tr><td><a href="/drugs/DB00412">Rosiglitazone</a></td><td>The moderate CYP2C8 inhibitor, Rosiglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rosiglitazone is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The strong CYP2C8 inducer, Secobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Secobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00398">Sorafenib</a></td><td>The strong CYP2C8 inhibitor, Sorafenib, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Sorafenib is initiated, discontinued to dose changed. </td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>The moderate CYP2C8 inhibitor, Tamoxifen, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Tamoxifen is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00560">Tigecycline</a></td><td>Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The moderate CYP2C8 inhibitor, Trimethoprim, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Trimethoprim is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00162">Vitamin A</a></td><td>Tretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking systemic tretinoin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>